Venous Thromboembolism Management in Pregnant Patients

Tech Vasc Interv Radiol. 2023 Jun;26(2):100901. doi: 10.1016/j.tvir.2023.100901. Epub 2023 Aug 5.

Abstract

Pulmonary embolism (PE) in pregnancy accounts for 10% of maternal deaths in the United States. As maternal morbidity and mortality continue to increase, it is imperative for all specialties interfacing with pregnant patients to understand the current research and guidelines surrounding risk stratification, diagnosis, and treatments of PE in pregnancy. Given the complexity of high-risk pregnancy-associated PE (PA-PE), that is, which is associated with hemodynamic instability or collapse, and the rising popularity of new technologies to treat high-risk PA-PE in the nonpregnant population, this review aims to emphasize the differences in diagnosis, risk stratification, and management of the pregnant and nonpregnant PE patients. Furthermore, this review will cover treatment paradigms that include anticoagulation versus advanced therapies such as systemic thrombolysis, surgical embolectomy, extracorporeal membrane oxygenation, and inferior vena cava disruption as well as the more novel therapies which fall under the umbrella term of catheter-based treatments. Finally, this review will include a case-based review of 2 patients with PA-PE requiring catheter-based therapies and their ultimate clinical outcomes.

Keywords: PE in pregnancy; PE thrombectomy; Pregnancy PE; Pulmonary embolism; Thrombectomy in pregnancy.

Publication types

  • Review

MeSH terms

  • Embolectomy / adverse effects
  • Female
  • Humans
  • Pregnancy
  • Pulmonary Embolism* / diagnostic imaging
  • Pulmonary Embolism* / therapy
  • Thrombolytic Therapy / adverse effects
  • Treatment Outcome
  • Vascular Diseases*
  • Venous Thromboembolism* / diagnostic imaging
  • Venous Thromboembolism* / therapy